Zobrazeno 1 - 10
of 5 327
pro vyhledávání: '"Sacubitril"'
Autor:
Tatsuki Yanagawa, Yuki Asai, Nobuyuki Zakoji, Shingo Hosoe, Yoshihiro Kondo, Shinnosuke Ootsuki, Hidekazu Kato, Maria Aoki, Yoshiaki Yamamoto, Takanori Yamamoto, Masaaki Takahashi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor (ARNI) that inhibits the degradation of endogenous natriuretic peptides. Therefore, ARNIs may increase the efficacy of human atrial natriuretic peptide (hANP), a
Externí odkaz:
https://doaj.org/article/f02e5a9fac234225a9d937c12c6f18cf
Autor:
Al Raddadi S, Almutairi M, AlAamer K, Alsalman A, Albalawi M, Almeshary M, Badreldin HA, Almodaimegh H
Publikováno v:
Drug, Healthcare and Patient Safety, Vol Volume 16, Pp 117-124 (2024)
Sultan Al Raddadi,1– 3 Majed Almutairi,1,3 Kholoud AlAamer,1,3 Abdulmahsen Alsalman,3,4 Maram Albalawi,5 Meshary Almeshary,1,3 Hisham A Badreldin,1,2,6 Hind Almodaimegh1– 3 1Department of Pharmaceutical Care, King Abdulaziz Medical City, Ministry
Externí odkaz:
https://doaj.org/article/461d2e197a854eee84e47c8a10f56c46
Autor:
Ludek Pavlu, Marek Vicha, Jakub Flasik, Jana Petrkova, Milos Taborsky, Tereza Kacirkova, Ondrej Holy
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 229-234 (2024)
Background and Aims. There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-
Externí odkaz:
https://doaj.org/article/d1f2b307edac453b86230ed6b0e4aba6
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Autor:
Antoine Garnier-Crussard
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-5 (2024)
Abstract Since 2014, sacubitril/valsartan (Entresto®) is widely prescribed for heart failure. Despite neprilysin inhibition’s benefits in heart failure, concerns about potential amyloid-beta (Aβ) accumulation and Alzheimer’s disease (AD) risk h
Externí odkaz:
https://doaj.org/article/76644807e1c6445890827294846cbe19
Autor:
Dong‐Yi Chen, Chun‐Chi Chen, Cheng‐Hung Lee, Chi‐Nan Tseng, Shao‐Wei Chen, Shang‐Hung Chang, Tien‐Hsing Chen, Pao‐Hsien Chu, I‐Chang Hsieh, Ming‐Shien Wen, Ming‐Lung Tsai, Ming‐Jer Hsieh
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2259-2271 (2024)
Abstract Aims The PIONEER‐HF and PARAGLIDE‐HF trials aimed to determine the efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients hospitalized for AHF. However, whether the inclusion and exclusion criteria of the
Externí odkaz:
https://doaj.org/article/3df3cbf84add40b389c311b6a71fb639
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract We assessed the real-world effectiveness of sacubitril/valsartan in patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) with an emphasis on those with older age (≥ 75 years) or with New York Heart Association (NY
Externí odkaz:
https://doaj.org/article/39c891947987435196a70a0075c976ec
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundThe mechanism underlying new-onset postoperative atrial fibrillation (POAF) in adult cardiac surgery is not well understood. However, efficient pharmacological methods to prevent and treat arrhythmic complications are still lacking. In the
Externí odkaz:
https://doaj.org/article/5ab34f20f1824fdc82f2d69a63849b3a
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
ObjectiveLevosimendan and Sacubitril/Valsartan are both potent pharmacotherapeutic agents in the clinical management of heart failure characterized by reduced ejection fraction. However, the limited efficacy of monotherapy and the lack of extensive c
Externí odkaz:
https://doaj.org/article/9f4784ff198a4b82b37477c02aed7e29
Autor:
Michele Correale, Damiano D’Alessandro, Lucia Tricarico, Vincenzo Ceci, Pietro Mazzeo, Raffaele Capasso, Salvatore Ferrara, Massimo Barile, Nicola Di Nunno, Luciano Rossi, Antonio Vitullo, Michele Granatiero, Mattia Granato, Massimo Iacoviello, Natale Daniele Brunetti
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 54, Iss , Pp 101492- (2024)
Background: Cardiac remodeling is an adverse phenomenon linked to heart failure (HF) progression. Cardiac remodeling could represent the real therapeutic goal in the treatment of patients with HF and reduced ejection fraction (HFrEF), being potential
Externí odkaz:
https://doaj.org/article/eb5dd89b2f8547ad8bd2f0ee8fbd728e